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Abstract
Background—Neuropeptide precursors are traditionally viewed as proteins giving rise to small 
neuropeptide molecules. Prodynorphin (PDYN) is the precursor protein to dynorphins, 
endogenous ligands for the κ-opioid receptor. Alternative mRNA splicing of neuropeptide genes 
may regulate cell- and tissue-specific neuropeptide expression and produce novel protein isoforms. 
We here searched for novel PDYN mRNA and their protein product in the human brain.
Methods—New PDYN transcripts were identified using nested PCR amplified from oligo(dT) 
selected full-length capped mRNA. Gene expression was analyzed by qRT-PCR, PDYN protein by 
western blotting and confocal imaging, dynorphin peptides by radioimmunoassay. Neuronal nuclei 
were isolated using fluorescence-activated nuclei sorting from postmortem human striatal tissue. 
Immunofluorescence staining and confocal microscopy was performed for human caudate 
nucleus.
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Results—Two novel human PDYN mRNA splicing variants were identified. Expression of one 
of them was confined to the striatum where its levels constituted up to 30% of total PDYN mRNA. 
This transcript may be translated into ΔSP-PDYN protein lacking 13 N-terminal amino acids, a 
fragment of signal peptide (SP). ΔSP-PDYN was not processed to mature dynorphins and 
surprisingly, was targeted to the cell nuclei in a model cellular system. The endogenous PDYN 
protein was identified in the cell nuclei in human striatum by western blotting of isolated neuronal 
nuclei, and by confocal imaging.
Conclusions and general significance—High levels of alternatively spliced ΔSP-PDYN 
mRNA and nuclear localization of PDYN protein suggest an essential nuclear function for this 
isoform of the opioid peptide precursor in human striatum.
Keywords
Neuropeptide precursor protein; prodynorphin; alternative splicing; nuclear localization; human 
brain
1. INTRODUCTION
A function of neuropeptide precursor proteins is to give rise to neuropeptides, small peptide 
molecules that serve as neurotransmitters, neuromodulators or neurohormones acting 
through the G-protein coupled receptors. The precursor molecules translocate into the 
endoplasmic reticulum where they fold and undergo posttranslational modifications, then 
transported to the Golgi apparatus and targeted to the regulated secretory pathway [1–4]. In 
endocrine cells, precursor proteins are cleaved to mature neuropeptides in the trans-Golgi 
network and secretory vesicles [1–6]. In neurons, the neuropeptide precursors are processed 
during transport from the perikaryon to axon terminals, or at these terminals and dendrites 
where they are stored in unprocessed form [7].
Splicing of precursor mRNA is essential for eukaryotic gene expression especially in the 
brain in which the most complex pattern of alternative splicing contributes to cell 
differentiation, neuronal migration and synaptogenesis [8]. Little is known about alternative 
mRNA splicing of neuropeptide genes that may regulate cell- and tissue-specific 
neuropeptide expression, subcellular localization of precursor proteins and neuronal 
plasticity, or produce novel protein isoforms.
The prodynorphin gene (PDYN) gives rise to dynorphins, the endogenous opioid peptides 
that are ligands for the κ-opioid receptor [9]. Dynorphins are expressed in the basal ganglia, 
hippocampus, cerebral cortex and spinal cord [10] and are essential for regulation of sensory 
processes [1, 5, 6], modulation of reward [2, 3], motor control [4] and stress-induced 
behavioral responses [11]. The canonical form of PDYN pre-mRNA consists of three 
introns, and four exons of which the 3rd and 4th encode for the full-length protein (FL-
PDYN mRNA) [12, 13] (Fig. 1A). Altogether, eight human PDYN transcripts FL1, FL2, 
splicing variants Sp1 and Sp2, and 5´-truncated Taf1, Taf2, T1, and T2 mRNAs were 
described in previous studies [13, 14]. Three variants (GTEx 1–3) of dominant FL-PDYN 
transcripts that differ in the length of exon 1, the presence of exon 2 and distribution in 
human brain were identified by RNA-seq analysis (GTEx Portal, http://www.gtexportal.org/
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home/) (Fig. 1A). Searching for novel PDYN mRNA, we here identified two PDYN splice 
variants, and characterized the expression levels and distribution in the human brain of one 
of them, i.e. ΔSP-PDYN. This transcript gives rise to a protein that lacks the 13 N-terminal 
aa, a fragment of the signal peptide. Surprisingly, ΔSP-PDYN ectopically expressed in a 
model cell line and the endogenous protein in human striatum, is located in the cell nuclei 
suggesting a nuclear function for this neuropeptide precursor protein.
2. MATERIALS AND METHODS
2.1. Postmortem human brain tissue
Brain tissues were collected from ten deceased subjects with no evidence of neuropathology 
and no known history of neuropsychiatric disease by KI Donatum at Forensic Medicine, 
Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden, by 
qualified pathologists under the full ethical clearance from the Stockholm Ethical Review 
Board. Donation was performed after an informed consent by the next of kin or by a 
registration as a donor by the deceased. Tissue samples of cerebellum, striatum (caudate 
nucleus, putamen and nucleus accumbens), dorsolateral prefrontal cortex and orbitofrontal 
cortex were obtained from seven subjects and used for gene expression validation by qRT-
PCR (Table 1, subjects 1–7). Samples from cerebellum and striatum were used for 
fluorescence-activated nuclei sorting followed by western blot and radioimmunoassay (Table 
1, subjects 8–10).
Sections of caudate nucleus used for analysis of ΔSP-PDYN intracellular localization by 
confocal microscopy were obtained from four subjects from the Postmortem Brain Core, 
Center for Psychiatric Neuroscience, University of Mississippi Medical Center, Jackson, 
MS, USA. The protocol for recruitment, tissue collection, and interviews was approved by 
the Institutional Review Boards of University Hospitals Case Medical Center, Cleveland, 
OH, and University of Mississippi Medical Center. Written informed consent was obtained 
from legally-defined next of kin for tissue collection and informant-based retrospective 
diagnostic interviews (Table 1, subjects 11–14). No subjects had evidence of head trauma, 
neurologic, neuropathological, or psychiatric disease.
2.2. RNA isolation and cDNA synthesis
Total RNA was purified using RNeasy Lipid Tissue Mini Kit (QIAGEN, Maryland, USA), 
treated with RNase–free DNase I on-column for 30 min at room temperature and stored at 
−80°C for further use. Total RNA amount was quantified by Nanodrop® (Nanodrop 
Technologies, Inc., USA). RNA Quality Indicator was analyzed by Eukaryote Total RNA 
StdSens assay using a Bio-Rad Experion instrument (Bio-Rad Laboratories, Hercules, CA, 
USA). For cDNA synthesis, total mRNA was reverse transcribed with PDYN-specific primer 
(Table 2, Fig. S1) using iScript Select kit (Bio-Rad Laboratories, Hercules, CA, USA). 
PDYN specific 3´-primer is complementary to the exon 4 sequence that was spliced out as 
an intron in ΔSP/NLS-PDYN mRNA, thus allowing detection of only ΔSP- but not ΔSP/
NLS-PDYN mRNA.
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2.3. Nested PCR
cDNA from human brain (FirstChoice® RACE-Ready cDNA Kit, Ambion) which is 
synthesized from high quality total RNA enriched for mRNA content by three rounds of 
oligo(dT) selection and amplified only from full-length, capped mRNA was used as a 
source. First round amplification was performed with DREmet43F and PDYN1086R 
primers (Table 2; Fig. 1B, C) on a Mastercycler (Eppendorf, Berlin, Germany) followed by 
digestion with BglII to eliminate the dominant FL1- and FL2-PDYN transcripts. In the 
second round amplification was performed with PDYN53F and PDYN1053R primers (Table 
2), the resulting PCR products were purified using a Illustra GFX™ PCR DNA and Gel 
Band Purification Kit (GE Healthcare, UK Limited, Little Chalfont, UK), digested with 
BglII and subjected to a third round of amplification with PDYN68F and PDYN1038R 
primers (Table 2). Two PCR products of 850 bp size (ΔSP-PDYN) and 560 bp size(ΔSP/
NLS-PDYN), were excised from the gel, purified using an Illustra GFX™ PCR DNA and 
Gel Band Purification Kit and sequenced in both directions. The following conditions were 
applied for the endpoint PCR; 95°C for 3 min followed by 40 cycles at 95.0°C for 15 s, 
60.0°C for 30 s and 72.0°C for 30 s.
2.4. Quantitative reverse transcription PCR (qRT-PCR)
qRT-PCR was performed on a CFX96™ Real-Time PCR Detection System (Bio-Rad 
Laboratories, Hercules, CA, USA) using SYBR Green Supermix (Bio-Rad Laboratories, 
Hercules, CA, USA). Primers were designed using Vector NTI advance 11 software (Table 
2, Fig. S1). The following conditions were applied for the two steps RT-qPCR reaction; 
95.0°C for 3 min followed by 40 cycles at 95.0°C for 10 s, annealing temperature for 61.5°C 
for 30 s. A relative quantification analysis was performed, based on an external calibration 
curve [15], constructed from purified ΔSP- and FL-PDYN PCR products. Melting curve 
analysis was performed to confirm the specificity of amplification and lack of primer 
dimers. To ensure correct amplification, PCR products were separated on agarose gel and 
sequenced in both directions.
2.5. Plasmid construction
cDNAs encoding FL- and ΔSP-PDYN were amplified by PCR using FL-pCMV4 [14] and 
ΔSP-pCMV4 primers (see Table 2), generating a BglII site at the 5´ end and a HindIII site at 
the 3´ end. This facilitated cloning into the BglII/HindIII sites of pCMV4 vector (Clontech, 
San Diego, CA, USA) to construct pCMV-FL-PDYN and pCMV-ΔSP-PDYN. pCMV-FL-
PDYN contains coding part of exons 3 and 4 and encodes FL-PDYN (254 aa), while pCMV-
ΔSP-PDYN with a 5´-truncated exon 3 and intact exon 4 gives rise to ΔSP-PDYN (241 aa). 
Sequencing was performed to check the correctness of both plasmids.
2.6. Cell culture and transfection
Rat insulinoma RINm-5F cells were cultured in RPMI-1640 medium with GlutaMAX 
(Gibco, Invitrogen, Paisley, UK) supplemented with 10% fetal bovine serum, penicillin and 
streptomycin in 5% CO2 and at 37°C. 2.0 × 105 cells per well were plated on four-well 
chamber slides (Lab-Tek, Nunc Inc., IL,USA) for immunocytochemistry analyses. 2.9 × 105 
cells were plated per 60-mm dish for the transfection procedure. Cells transfected with 
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plasmid DNA using Lipofectamine 2000™ (Invitrogen, Carlsbad, CA, USA), were 
harvested for protein analysis and immunostaining. For radioimmunoassay transfected cells 
were cultured for 18 h prior harvesting in the absence of cell medium.
2.7. Fluorescence-activated nuclei sorting (FANS)
Isolation of neuronal nuclei was performed as previously described [16, 17]. In brief, 1 g of 
thawed tissue from each human striatum and cerebellum was disrupted in Dounce 
homogenizer in lysis buffer (0.32 M sucrose, 5 mM CaCl2, 3 mM Mg (CH3COO)2, 0.1 mM 
EDTA, 10 mM Tris HCl (pH 8.0), 0.1% Triton X-100, 1 mM DTT), the suspension was 
loaded onto a 15% sucrose cushion and centrifuged at 30,000 × g for 2.5 hours at 4°C. 
Nuclei pellet was resuspended in PBS, monoclonal anti-NeuN antibody (Millipore, Billerica, 
MA) conjugated with Zenon anti-mouse Alexa 647-IgG (Molecular Probes) was added to 
the suspension and incubated at 4°C for 45 min. Neuronal, NeuN positive (NeuN(+)) nuclei 
were separated from non-neuronal, NeuN negative (NeuN(−)) nuclei using the FACSDiVa 
high-speed cell sorter (Becton Dickinson, Heidelberg, Germany). Nuclear suspension was 
centrifuged at 30,000 × g for 3 min and nuclear pellets were resuspended in PBS and stored 
at −80°C.
Two quality controls for FANS procedure were performed. First control includes the 
reanalyzing of the sorted populations by flow cytometry. 20 µl of the sorted nuclei was 
resuspended in 80 µl of PBS with a following flow cytometry analysis using the same gate 
setting as for FANS. The purities of NeuN(+) and NeuN(−) nuclei fractions were 97.3 
± 0.8%, and 99.95 ± 0.1%, respectively. Second quality control performed by analysis of 
expression of neuronal markers, RBFOX3 coding for NeuN and ENO2 coding for enolase 2 
as well as GFAP, an astroglial marker in neuronal and non-neuronal FAN-sorted fractions by 
droplet digital PCR [18]. This analysis demonstrated clear separation of neuronal and non-
neuronal nuclei by FANS, with more than 90% of RBFOX3 and ENO2 expression confined 
to neuronal nuclei, and more than 97% of GFAP expression confined to non-neuronal nuclei 
(manuscript in preparation).
2.8. Anti-human PDYN and anti-dynorphin antibodies
Rabbit polyclonal antisera were generated against human PDYN C-terminal fragment (CTF; 
aa 241–254) and PDYN-derived opioid peptides (Dyn A1–17, Dyn B1–13, and Leu-
enkephalin-Arg) all conjugated with keyhole limpet hemocyanin via Cys added to their N 
terminus [7, 14, 19]. IgG fractions were purified with Protein A-Sepharose and extensively 
characterized. Anti-PDYN CTF antibody demonstrating high specificity was used for 
western blot (WB) and immunohistochemistry (IHC) [7]. Anti-Dyn A antibody did not react 
with PDYN in WB and IHC experiments when HeLa or PC12 cells transfected with pCMV-
PDYN plasmid were analyzed; these cells do not process PDYN to dynorphins. Negative 
controls included pre-immune IgG fractions, and primary antibody blocked with 10 nM of 
antigenic human PDYN CTF aa 241–254 or related rat Pdyn C-terminal fragment (aa 235–
248), which has 7 mismatches in the 15 amino acid sequence from the human CTF. In WB 
and IHC experiments, the PDYN signal was blocked by preincubation of the antiserum with 
10 nM of the human PDYN CTF, but not with rat Pdyn CTF. The specificity of these 
antibodies has been reported earlier [14, 20].
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Anti-Dyn A antibody demonstrated 100% molar crossreactivity with Dyn A(9–17) and 0.1% 
molar crossreactivity with Dyn B, Dyn A(1–8), a-neoendorphin, Leu-enkephalin, and big 
dynorphin. Anti-Dyn B antiserum showed 100% molar crossreactivity with big dynorphin, 
0.8% crossreactivity with Leu-morphine (29 aa C-terminally extended Dyn B), and 0.1% 
crossreactivity with Dyn A(1–17), Dyn A(1–8), a-neoendorphin, and Leu-enkephalin. Dyn 
A, Dyn B, and Leu-enkephalin-Arg RIA readily detected these peptides in brain tissues of 
wild-type (WT) mice [21] and rats [20], whereas did not detect any peptide 
immunoreactivity in the striatum, hippocampus, and frontal cerebral cortex of Pdyn 
knockout mice used as negative controls [22], demonstrating high specificity of this method 
and the absence of interference with other peptides present in tissue extracts.
2.9. Immunofluorescent cell staining
RINm-5F cells transfected with plasmid coding for ΔSP-PDYN or FL-PDYN cDNA, or 
mock transfected with CMV-vector plasmid were fixed and incubated with primary anti-
human PDYN CTF, (1:600), and anti-dynorphin A (1:500) 18 hours at +4°C followed by 
incubation with secondary goat anti-rabbit antibody conjugated with Alexa Fluor 488 
(1:1000) (Molecular Probes, Ltd, Paisley, UK).
2.10. PDYN immunofluorescent staining in human caudate nucleus
Snap frozen human post-mortem tissue samples of caudate nucleus obtained from four 
subjects (see Table 1, for demographic data and tissue characteristics) were cryosectioned (8 
sections 20 µm each) and mounted on superfrost+ microscope slides. Slides were stored at 
−80°C until analysis. For the immunofluorescence (IF) staining sections were placed in a 
freshly prepared 0.1 M phosphate buffer (pH 7.4) solution containing 4% paraformaldehyde. 
After washing in phosphate buffered saline containing 0.03% H2O2 to block endogenous 
peroxide, sections were incubated with rabbit polyclonal antibody raised against human 
PDYN CTF (1:4,000) in 0.1 M phosphate buffer contained 0.3% TX-100 and 0.1% NaN3 for 
48 hours at 4°C. Sections were repeatedly washed in Tris-buffered saline (pH 7.4) 
containing 0.5% Tween20 (TNT) and were blocked with Tris-buffered saline containing 
2.5% blocking reagent (TNB, Perkin Elmer, Waltham, USA) for 30 minutes at room 
temperature. After that sections were incubated in TNB buffer containing horseradish 
peroxidase conjugated secondary anti-rabbit IgG antibody raised in swine (1:200; DAKO, 
Glostrup, Denmark). After washing in TNT buffer the sections were incubated in 
amplification diluent containing fluorescein or Cy5 conjugated tyramine (1:100; Perkin 
Elmer, Waltham, USA). Nuclei were visualized using Hoechst 33342 (1:10,000, Biotium, 
CA, USA) in combination with SYTOX green (1:300; Life Technologies, Stockholm, 
Sweden).
Lipofuscin-autofluorescence was blocked by incubating the sections in 70% EtOH 
containing 1% Sudan black. Slides were mounted using ProLong Gold antifade reagent 
(Invitrogen, Waltham, Massachusetts, USA) and precision cover glasses (Marienfeld, Lauda-
Köningshofen, Germany).
The specificity of anti-PDYN antibody was determined by an adsorption test and 
immunostaining with preimmune rabbit IgG. Briefly, rabbit antibody against PDYN 
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(1:4,000) were preincubated with PDYN antigen (human PDYN CTF 241–254 aa peptide, 
100 nM) overnight at 4°C. The mixture was applied to a section of human caudate putamen 
and immunoreactivity was determines as described above. For comparison, adjacent sections 
were incubated with rabbit anti PDYN (1:4,000; positive control) and pre-immune rabbit 
IgG (1:4,000; negative control). Results of adsorption test were visualized with 
epifluorescence microscopy. Adsorption test demonstrated elimination of the specific 
immunoreactivity on human caudate nucleus tissue. Pre-immune IgG did not produce 
positive staining with minor reactivity in in capillaries.
2.11. Epifluorescence microscopy
Entire slides were scanned using a slide-scanning microscope (Vslide, Metasystems, 
Altlussheim, Germany) equipped with 10 × and 20 × objectives and the appropriate 
excitation and emission filter sets for detection SYTOX green (504–523 nm) and cy5 (625–
670 nm). After scanning individual field of view images were stitched and used for 
identification the regions of interest.
2.12. Confocal microscopy and image processing
Fluorescent images of the RINm-5F cells were acquired with a Nipkow spinning disk 
confocal system (Yokogawa CSU-10; Yokogawa Electric Corporation, Tokyo, Japan) 
attached to a Diaphot 200 microscope (Nikon, Kanagawa, Japan) and equipped with a 
60×1.40/NA oil immersion objective (Nikon). Fluorescence was excited at 488 nm with 
argon ion laser (Melles-Griot, Didam, The Netherlands) and detected at 520/35 nm using 
cooled EM-CCD camera (iXon+ DU888; Andor, Belfast, Northern Ireland, UK) under 
MetaFluor software control (Molecular Devices Corp., Downingtown, PA).
Images of the human caudate nucleus were acquired by an Olympus FV1000 confocal laser 
scanning microscope (Olympus) equipped with a 20×/0.95W XLUMPlanFI objective. 
Emission spectra for each dye were limited as follows: Hoechst (361–497 nm) and Cy5 
(630–647 nm). For co-localization analysis of PDYN and Hoechst z-stacks of 24 images 
were acquired with a depth interval of 0.5 µm. The open source platform Image J (NIH, 
MD) was used for 3D projections and orthogonal co-localization analysis.
2.13. Dynorphin radioimmunoassay (RIA)
The procedure was described elsewhere [7, 14, 23]. Briefly, cell extracts in 1 M acetic acid 
and cell culture medium mixed with acetic acid were boiled at 95°C for 5 min. After 
centrifugation, supernatant was loaded on a SP-Sephadex ion exchange C-25 column, 
peptides were eluted and analyzed by RIA. Protein concentrations were estimated by DC 
protein assay (Bio-Rad, Laboratories, Hercules, CA, USA).
Total content of PDYN protein and PDYN derived opioid peptides in the NeuN(+) and 
NeuN(−) nuclei isolated from human striatal and cerebellar tissues was determined using 
procedure based on liberation of Leu-enkephalin-Arg (LER), a PDYN marker from PDYN / 
PDYN fragments by trypsin digestion followed by LER RIA as described earlier [7]. 
Aliquots containing 1.0×106 of striatal or cerebellar NeuN(+) and NeuN(−) nuclei were 
heated up to 95°C (5 min). After centrifugation, supernatant was collected and incubated 
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with immobilized TPCK-trypsin (Biochemical Corporation, Lakewood, NJ, USA) in 0.1 M 
NH4HCO3 buffer, pH 8.0 for 16 h at 37°C to liberate LER from PDYN protein and its 
fragments. Reaction was stopped by addition of acetic acid (1 M final concentration) and 
heating at 95°C for 5 min. After centrifugation, the mixture was subjected to SP-Sephadex 
C-25 chromatography and LER was analyzed by RIA. The content of PDYN was calculated 
in fmol of protein assuming that a PDYN molecule contains three LER copies; data was 
obtained in three independent experiments. Aliquots of nuclear extracts taken prior to the 
digestion, or trypsin alone did not produce any signal in LER RIA.
2.14. Western blotting
Cell nuclei isolated from striatal and cerebellar tissues and RINm-5F transfected cells for 
analysis of PDYN were extracted with SDS buffer (0.45 M Tris-HCl, pH 8.5, 2.5% glycerol 
and 4% SDS) supplemented with DTT and Compete Inhibitor Cocktail (Roche, Basel, 
Switzerland), as described previously [23]. Protein concentrations were determined with DC 
protein assay (Bio-Rad, Laboratories, Hercules, CA, USA) and Pierce assay (Thermo 
Scientific Life Science Research Products, Rockford, IL, USA) for sorted nuclei and 
transfected cells, respectively. Proteins were resolved by SDS-PAGE on 10% Tricine gels, 
transferred onto nitrocellulose membranes (Schleicher and Schuell, Keene, USA), and 
stained with MemCode reversible Protein Stain Kit (Pierce, Rockford, IL), as described 
previously [7, 14]. Membranes blocked with 5% nonfat dry milk were probed with anti-
PDYN CTF antibody (1:1000) and were incubated with anti-rabbit horseradish peroxidase-
conjugated secondary antibody (Bio-Rad Laboratories, Hercules, CA, USA) (1:12500).
2.15. Sequence analyses
FL-PDYN and ΔSP-PDYN sequences were analyzed for the presence of signal peptide (SP), 
putative nuclear localization signal (NLS), and leucine-rich nuclear export signal (NES) 
sequences (SignalP V4.0, cNLS Mapper, PSORT II, and NetNES 1.1).
3. RESULTS
The PDYN gene produces several RNA variants encoding for the full-length (FL) and 
truncated PDYN proteins (Fig. 1A). The dominant FL1-PDYN and three transcripts with 
alternative TSS (transcription start site), such as FL2 and testis-specific Taf I, and Taf II 
transcripts, encode full-length PDYN protein. RNA-seq analysis of the human transcriptome 
demonstrated that PDYN transcripts dominant in the brain differ in the length of the first 
exon and the presence of the second exon (GTEx Portal, http://www.gtexportal.org/home/). 
PDYN transcript Sp1 may produce PDYN protein isoforms that lack a segment between the 
signal peptide and the opioid sequences. Another PDYN transcript (Sp2) with an alternative 
TSS, alternative 5´ splice site (SS) selection in exon 1, exons 2 and 3 skipping and 
alternative 3´ SS selection in exon 4 could possibly be translated from third methionine 
codon (Met146). Other PDYN transcripts initiated within the coding part of exon 4 may 
result in PDYN protein isoforms that are N-terminally truncated T1 and T2 translated either 
from the third or fourth methionine codon (Met146 or Met198), respectively.
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3.1. Novel human PDYN splice variants
Having identified several PDYN transcripts lacking exon 2 [13, 14], we searched for other 
such transcripts in the human brain as a part of strategy aimed to identify all types of PDYN 
mRNAs. Exon 2-containing transcripts including dominant FL1 and FL2 mRNAs were 
eliminated by treatment of cDNA with BglII endonuclease, which cleavage site is located in 
exon 2 (Fig. 1B, C). After three consecutive rounds of nested PCR each followed by BglII 
treatment, two novel alternatively spliced PDYN transcripts ΔSP-PDYN and ΔSP/NLS-
PDYN were isolated (Fig. 1, B–E). ΔSP-PDYN is 850 nt long, consists of three exons and 
two introns with alternative 5´SS selection in exon 1 (lacking 71 nt), exon 2 skipping (60 nt) 
and alternative 3´ SS selection in exon 3 (lacking 36 nt). ΔSP-PDYN also retained non-
canonical exon 3–4 junction. The consensus sequence presented in the exon 3–4 junction 
likely indicates the U12-dependent intron excision [24]. The exon 2–3 junction was absent 
in the ΔSP-PDYN mRNA, and a novel exon 1–3 junction is non-canonical (see Fig. S1). 
Alternative splice sites are usually weaker than constitutive sites, and alternative exons or 
introns often have an atypical composition [25, 26]. The ΔSP-PDYN mRNA lacking the first 
methionine codon (Met1) may be translated from the second methionine codon (M14) giving 
rise to a 241 aa protein in which the N-terminal 13 amino acids of the signal peptide 
sequence are absent (Fig. 1E).
The second novel PDYN splice variant in which sequences coding for SP and NLS (nuclear 
localization signal) are absent (ΔSP/NLS-PDYN) is 560 nt long. It resembles ΔSP-PDYN 
but is shorter due to the presence of two alternative introns in exon 4: 307 nt including the α-
neoendorphin, dynorphin A (Dyn A) and 5´-part of dynorphin B (Dyn B) encoding 
sequences and 31 nt in the 3´-untranslated region (Fig. 1D). In ΔSP/NLS-PDYN the 
alternative intron junction in exon 4 is non-canonical (see Fig. S1). This mRNA may be 
translated into a 127 amino acid protein deficient in α-neoendorphin and dynorphin A 
sequences (Fig. 1E).
3.2. ΔSP-PDYN transcript expression is brain region-specific
For analysis of total PDYN transcripts, PCR primers targeted to the exon 3–4 junction 
present in the most dominant PDYN isoforms, were used (Fig. S1). To selectively detect 
ΔSP-PDYN transcript, forward PCR primer was designed to span the novel exon 1–3 
junction (Fig. S1). The cDNA for this experiment was synthesised using a 3´-primer 
complementary to the exon 4 sequence that was spliced out as an intron in ΔSP/NLS-PDYN 
mRNA, thus allowing detection of ΔSP- but not of ΔSP/NLS-PDYN mRNA (Fig S1). The 
levels of ΔSP-PDYN mRNA were high in the human nucleus accumbens, caudate nucleus 
and putamen, while negligible in frontal lobes (orbitofrontal cortex and dorsa-lateral 
prefrontal cortex) and the hindbrain (cerebellum) despite robust PDYN mRNA expression 
(Fig. 2A). In the striatal subregions, ΔSP-PDYN mRNA constituted a substantial fraction, 
20– 30% of the total PDYN mRNAs containing an exon 3–4 junction, including FL-PDYN 
mRNAs (Fig. 2B), and strongly correlated (R = 0.98; R, Pearson correlation coefficient) 
with the latter in all tree striatal subregions.
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3.3. Unprocessed ΔSP-PDYN is targeted to the nuclei in model cell line
Initiation of ΔSP-PDYN translation from Met14, processing of this protein to opioid peptides 
and its subcellular localization was studied using the rat insulinoma cell line RINm5F as a 
model system. These cells do not express endogenous Pdyn but may process ectopically 
expressed neuropeptide precursor proteins to mature neuropeptides (36). RINm5F cells were 
transfected with pCMV-ΔSP-PDYN or pCMV-FL-PDYN plasmids, or pCMV vector 
resulting in synthesis of proteins with a very similar molecular weight about 28 kDa that 
corresponded to the calculated size of the PDYN molecule (Fig. 3A). FL-PDYN protein was 
processed to Dyn A, Dyn B and LER (leucine-enkephalin-arginine) that were identified in 
cell extracts and culture media by RIA (Fig. 3 B, C). Whereas, no opioid peptides were 
generated in the cells expressing the ΔSP-PDYN protein (Fig. 3B).
The subcellular localization of ΔSP- and FL-PDYN proteins was visualized using confocal 
microscopy of transfected RINm-5F cells after cell labeling with antibody against the PDYN 
C-terminal fragment (CTF) that is present in both proteins, and with anti-Dyn A antibody 
directed against a mature opioid peptide. In transfected cells, FL-PDYN immunoreactivity 
identified with both antibody showed similar labeling patterns; immunoreactive PDYN 
formed punctate clusters characteristic for localization in the endoplasmic reticulum and 
Golgi lamellae (Fig. 3D). In contrast, the ΔSP-PDYN isoform was densely packed in the cell 
nucleus. Weak or no ΔSP-PDYN produced signal was seen with anti-Dyn A antibody. No 
labeled cells were observed in mock-transfected cells, with a prebleed IgG fraction used for 
immunostaining, or when antiserum was preincubated with 10 nM of the human CTF. 
Preincubation of the antiserum with rat CTF did not affect the labeling. Thus, ΔSP-PDYN 
ectopically expressed in RINm-5F cells is targeted to the cell nucleus where it is not 
processed to opioid peptides.
3.4. PDYN is localized in neuronal nuclei in human striatum
The NLS score for human PDYN predicts a high probability of nuclear localization for ΔSP-
PDYN (Table S1). We therefore next examined whether PDYN is localized in the cell nuclei 
in human striatum (caudate nucleus), an area with high ΔSP-PDYN expression levels. 
Neuronal nuclei were isolated from frozen human tissues using fluorescence-activated nuclei 
sorting. Neuronal nuclei were labeled with antibody against NeuN, a neuronal marker. This 
antibody recognizes nuclei of mature neurons, but not those of neural progenitors and glial 
cells [27]. Human cerebellar tissue was used as negative control; PDYN expression is low in 
this tissue and no ΔSP-PDYN mRNA was detected (Fig. 2A).
PDYN protein in isolated neuronal and non-neuronal nuclei, was analyzed by RIA of LER, a 
PDYN marker [28] after treatment of nuclear extracts with trypsin, and by western blotting 
(Fig. 4A, B). Digestion with trypsin liberates LER from the precursor protein [7]. The levels 
of liberated LER in the fraction of neuronal nuclei were 4-fold higher than that in non-
neuronal nuclei isolated from human striatum (Fig. 4A). The amount of the liberated LER in 
both neuronal and non-neuronal nuclei prepared from cerebellum was below the detection 
limit (Fig. 4A). Western blot analysis of striatal neuronal nuclei identified immunoreactive 
PDYN protein as a single band with molecular size of 28 kDa that corresponded to 
unprocessed FL- and ΔSP-PDYN proteins. No PDYN immunoreactivity was evident in 
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neuronal and non-neuronal nuclei from cerebellum and non-neuronal nuclei from striatum 
(Fig. 4B).
Immunofluorescent labeling of human caudate nucleus sections of with anti-h-PDYN CTF 
antibody followed by confocal 3D reconstruction identified immunoreactive PDYN located 
in the neuronal cell nuclei and cytoplasm (Fig. 4C–E). The confocal microscope orthogonal 
projections on the acquired images demonstrated that PDYN immunoreactivity (red) was co-
localized with the Hoechst (green) nuclear staining (Fig. 4E). No PDYN was seen when 
anti-PDYN CTF antibody was omitted (data not shown), replaced with rabbit IgG or was 
inactivated by antigen peptide adsorption (Fig. S2). Taken together molecular and immuno-
labeling experiments strongly support the hypothesis on localization of PDYN protein in 
neuronal nuclei in human striatum.
4. DISCUSSION
The present study identified two novel alternatively spliced ΔSP- and ΔSP/NLS-PDYN 
mRNAs that both lack exon 2 and a fragment of exon 3. In the striatum, the expression 
levels of ΔSP-PDYN mRNA were substantial constituting up to 30% of total levels of PDYN 
mRNA molecules, while in the dl-PFC, orbitofrontal cortex and cerebellum were negligible. 
This marked difference suggests a specific function of ΔSP-PDYN in the striatum.
Novel PDYN mRNAs may give rise to PDYN proteins with the N-terminally truncated 
signal peptide. Analysis of the amino acid sequence the cNLS Mapper predicted the 
existence of a bipartite NLS in the opioid peptide domain of the ΔSP-PDYN. The PDYN 
NLS (179RKYPKRSSEVAGEGDGDSMGHEDLYKRYGG209) shows a high score and 
consists of a fragment joining α-neoendorphin and Dyn A sequences, four C-terminal and 
three N-terminal aa of these peptides, respectively, and two adjacent to them pairs of basic 
amino acids representing processing sites. The probability of ΔSP-PDYN to be located in the 
cell nuclei predicted by the PSORT II program is 39%, while that of FL-PDYN is 11%. The 
NLS encoding sequence is spliced out in the ΔSP/NLS-PDYN mRNA. Due to the signal 
peptide truncation, the cryptic bipartite NLS may become functional and target the ΔSP-
PDYN protein into the cell nuclei. Indeed, ΔSP-PDYN was located in the cell nuclei when 
ectopically expressed in a model cell line, and in neuronal nuclei in human striatum. A 
functionality of the predicted NLS was validated in our previous study (see Fig. 7 in [14]). 
Specifically, Sp2-PDYN mRNA generated by alternative splicing and T1- and T2-PDYN 
mRNAs transcriptionally initiated within the coding part of exon 4 were identified in the 
human brain [14]. Sp2 and T1 mRNAs gave rise to the 12 kDa T1-PDYN protein translated 
from Met146 (Fig. 1A). T1-protein lacks a signal peptide but retains the predicted bipartite 
NLS and was located in the cell nucleus when ectopically expressed in COS1 cells. In 
contrast, the T2-PDYN protein translated from the Met198 codon and lacking the predicted 
NLS (Fig. 1A) resides in the cytoplasm [14]. Targeting of T1- but not T2-protein to the cell 
nuclei demonstrated functional efficacy of the predicted bipartite NLS.
Consistently with model cellular data, a nuclear PDYN isoform was identified by western 
blot and radioimmunoassay in neuronal nuclei isolated from human striatum using 
fluorescence-activated nuclei sorting. Immunofluorescence staining and confocal 
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microscopy of the human caudate nucleus sections confirmed nuclear localization of the 
PDYN isoform. The molecular size of PDYN molecules in the neuronal nuclei was similar 
to that of FL-PDYN, suggesting that the nuclear PDYN immunoreactivity visualized in the 
human brain originates from ΔSP-PDYN, but not the shorter T1-protein.
Several previous studies support the hypothesis on a nuclear localization and nuclear 
functions of neuropeptide precursor proteins. An early bioinformatics analysis suggested 
that the opioid precursors PDYN and PENK may function as DNA-binding proteins on the 
basis of the presence of zinc-finger and helix-loop-helix domains, together with the 
similarity with hunchback, lil-1, tal and twist transcription factors [29]. Similar segments 
include enkephalin sequences which are parts of heptapeptide repeats characteristic of an 
alpha-helical coiled-coil structure distinctive of an amphipathic helix-loop-helix DNA-
binding motif. The opioid precursors also have cystein-rich regions characteristic of zinc-
finger domains in transcription factors. The cysteines forming zinc-finger domains are 
perfectly conserved in opioid peptide precursors.
Consistently with our human findings, our prior electron microscopic study identified 
immunoreactive Pdyn protein located on the nuclear membrane, and dynorphin A on the 
nuclear pore and inside the neuronal nuclei in rat nucleus accumbens [19]. In somata of the 
same neurons, Pdyn was located on the smooth endoplasmic reticulum and Golgi lamellae. 
Nuclear localization of another neuropeptide precursor protein, proenkephalin (PENK) in 
embryonic fibroblasts and in myoblasts in vitro was demonstrated by Spruce and co-workers 
[30]. Multiple antigenic domains of the endogenous nuclear PENK were unmasked in cells 
undergoing differentiation or entering growth arrest. PENK ectopically expressed in cell 
lines was localized exclusively in the cytoplasm, however, targeted to the nucleus when 
mutated at the first ATG codon, or when devoid of its signal peptide sequence. The authors 
speculated that alternate initiation of transcription, alternate splicing or initiation of 
translation from upstream in-frame CUG codons could lead to a PENK translation product 
devoid of a functional signal peptide, which is capable of nuclear translocation. The 
endogenous nuclear PENK may be physically associated with two transcription factors, p53 
and the RelA(p65) subunit of NF-κB, and with the co-repressor histone deacetylase 
suggesting participation of this protein in transcriptional repression complexes involved in 
apoptosis and cell survival [31].
In conclusion, the concept of nuclear localization and functions of neuropeptide precursors 
complementing to the general view on these proteins as molecules destined to be cleaved 
into short neuropeptides, gains experimental support. A functional role of ΔSP-PDYN 
should be elucidated, and its molecular partners and targets identified. This is especially 
important in the light of the recent identification of dominant pathogenic PDYN missense 
mutations that cause profound neurodegeneration in the human brain [23, 32–34]. These 
mutations are clustered in the opioid domain overlapping with NLS sequence, and may 
affect the biogenesis and trafficking of this protein that in turn may contribute to 
neuropathological changes. In general terms, dysregulation of complex PDYN 
transcriptional and translational mechanisms affecting a generation of canonical and nuclear 
PDYN proteins may define human pathological conditions including chronic pain and 
neurodegenerative diseases, in which a pathogenic role of PDYN is firmly established but 
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which mechanisms that are not mediated through opioid receptors have not yet been 
elucidated [35, 36].
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Refer to Web version on PubMed Central for supplementary material.
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Dyn A dynorphin A
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HIGHLIGHTS
• Two novel splicing variants of human PDYN mRNA have been identified.
• A novel ΔSP-PDYN splicing variant is mostly expressed in human striatum.
• ΔSP-PDYN protein lacks a fragment of signal peptide (SP).
• ΔSP-PDYN is not processed to mature dynorphins but targeted to the cell 
nuclei in a model cellular system.
• Unprocessed, likely ΔSP-PDYN is localized in neuronal nuclei in human 
striatum.
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FIGURE 1. Structure of known and identification of novel PDYN transcripts and proteins
A. Previously described PDYN transcripts coding for the full-length (FL) and truncated 
proteins. The dominant FL1-PDYN and transcripts identified using RNA-Seq that differ in 
the length of the first exon and the presence of the second exon (GTEx 1–3), as well as three 
transcripts with alternative TSS, FL2 and testis-specific Taf I and Taf II transcripts, encode 
FL-PDYN protein. Other PDYN isoforms such as alternatively spliced Sp1 and Sp2 and 
transcripts initiated within the coding part of exon 4 (T1 and T2) may produce truncated 
PDYN proteins. Curved arrows show position of the translation initiation (TI).
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B. Scheme of novel transcript identification. Human brain RACE-Ready cDNA was 
amplified in three rounds of nested PCR followed by digestion with BglII to eliminate the 
dominant FL-PDYN transcripts. The procedure allowed amplification of minor PDYN 
mRNA isoforms which then were analyzed by sequencing.
C. Structure of PDYN mRNAs consisting of four exons (boxes) and three introns (lines), and 
the localization of the primers used in the nested PCR are shown, not to scale. F and R 
depict forward and reverse primers (not to scale). αNE, DA and DB are the α-neoendorphin, 
dynorphin A and dynorphin B encoding sequences.
D, E. FL-PDYN and alternatively spliced ΔSP- and ΔSP/NLS-PDYN mRNA isoforms (D), 
and corresponding protein products (E). 3´-fragment of exon 1, exon 2 and 5´-fragment of 
exon 3 are spliced out in ΔSP- and ΔSP/NLS-transcripts. Two new introns are present in 
ΔSP/NLS mRNA isoform in exon 4 region; one of them overlaps with the dynorphin 
encoding domain, while another is located in the 3´-UTR (D). Signal peptide is truncated in 
both ΔSP- and ΔSP/NLS-PDYN. Putative NLS sequence is located in the dynorphin domain 
in FL- and ΔSP-PDYN but is absent in ΔSP/NLS-PDYN (E).
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FIGURE 2. The ΔSP-PDYN expression profile in the human brain
A. The expression levels of mRNAs for ΔSP-PDYN versus dominant PDYN transcripts. 
Levels were normalized to µg of total RNA. Data are shown as mean ± SEM for nucleus 
accumbens (NAc); caudate nucleus (Cd); putamen (Put); orbitofrontal cortex (OFC); 
dorsolateral prefrontal cortex (PFC); cerebellum (Cbl). For Put n = 5 human subject; for 
other brain areas n = 4 subjects.
B. ΔSP-PDYN mRNA as percentage of dominant PDYN mRNA levels, which have a 
canonical junction of exons 3–4 and include FL1-, FL2- and ΔSP-PDYN mRNAs. Data is 
shown as mean ± SEM.
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FIGURE 3. Processing and subcellular localization of ectopically expressed ΔSP- and FL-PDYN 
in RINm-5F cells
A. ΔSP- and FL-PDYN proteins analyzed by western blotting with anti-PDYN CTF 
antibody in RINm-5F transfected cells.
B, C. The levels of prodynorphin derived dynorphin A (Dyn A), dynorphin B (Dyn B) and 
Leu-enkephalin-Arg (LER) in the RINm-5F transfected cells (B) and in the culture media 
(C) analyzed by RIA. The cells were transfected with pCMV vector (mock), pCMV-ΔSP-
PDYN or pCMV-FL-PDYN. Data were normalized to the levels in mock transfected cells 
and are shown as mean ± SEM; n = 3 experiments.
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D. Subcellular localization of ΔSP-PDYN protein in RINm-5F cells observed under confocal 
fluorescence microscopy. Transfected cultures were immunolabeled with antibodies against 
PDYN CTF or dynorphin A. Images were taken with × 100 objective and × 5 electron zoom 
factor. Scale bar, 30 µm.
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FIGURE 4. ΔSP-PDYN is targeted to the neuronal nuclei in human striatum
A. The levels of PDYN derived peptide LER in neuronal and non-neuronal nuclei isolated 
by FANS from human striatal (Str) and cerebellar (Cbl) tissue samples. LER, a PDYN 
marker was analyzed by RIA. The amount of the liberated LER in both neuronal and non-
neuronal nuclei prepared from cerebellum was below the detection limit. Equal amount of 
neuronal and non-neuronal nuclei (106 nuclei) isolated from each tissue sample were 
analyzed. Data is shown as mean ± SEM, n = 2 subjects. Data was normalized to 1 µg of 
protein.
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B. PDYN proteins analyzed by western blotting in neuronal and non-neuronal nuclei isolated 
by FANS from human striatal (Str) and cerebellar (Cbl) tissue samples. Equal amount of 
neuronal and non-neuronal nuclei (106 nuclei) isolated from each tissue sample were 
analyzed. Ectopically expressed in RINm-5F cells FL-PDYN was used as a positive control, 
producing a single band with molecular size of 28 kDa that corresponded to unprocessed 
PDYN protein.
C–E. PDYN immunoreactivity was detected in the neuronal cell nuclei and cytoplasm in the 
human caudate nucleus. The brain sections were stained for ΔSP-PDYN protein with anti-
PDYN CTF antibody (red) (C) and for nuclei with Hoechst (green) (D). Representative 3D 
confocal reconstruction projections demonstrates double labeling (yellow) of neuronal 
nuclei (arrows) (E) indicating nuclear localization of PDYN isoform. Confocal images of Z-
stacks of 24 images acquired with a depth interval of 0.5 µm of the human caudate nucleus. 
Analysis shows that PDYN is present in the nucleus. The center image is the X-Y view, the 
images below and right are orthogonal projections in the X-Z and Y-Z planes (cross section 
at the yellow line). n = 4 subjects. Images were taken with 20 × /0.95W XLUMPlanFI water 
objective. Scale bar, 20 µm.
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TABLE 2
Primers sequences used for cDNA synthesis, identification of novel isoforms, qRT-PCR and plasmid 
construction.
Primer name Primer sequence (5′ – 3′) Amplicon size
(bp)
Assay
ΔSP-PDYN F: 5′ -GAGGCCCCTGTCCTGGCTGCC-3′
R: 5′ -GGGAGCAAATCAGGGGATTG -3′
130 qRT-PCR
PDYN Ex3-4 F: 5′ -CACCACAGCGGACTGCCTGT -3′
R: 5′ -AGCAGGGCAGCCTGGCATTG -3′
111 qRT-PCR
706R 5′ - GGTCCTCCTCAGCGAGATAGAGT-3′ - Reverse transcription
DREmet43
PDYN1086
F: 5′-GGCTTTGGTGGTGTTCACAGCT-3′
R: 5′-GTACACAATGCTGAGCTGAGCAT-3′
1043 Nested PCR, 1st round
PDYN53
PDYN1053
F: 5′-CCTCTTTGGCACCTCCTCCCAA-3′
R: 5′-GGCACATATAAGAGGATGAATGAATG-3′
1000 Nested PCR, 2st round
PDYN68
PDYN1038
F: 5′-CCCAAGCCGGAGTCAAGGAG-3′
R: 5′-TGAATGAATGCACTCCAACCTGAA-3′
970 Nested PCR, 3st round
ΔSP-pCMV4 F: 5′ -CCGCCAGATCTACCATGTTCCCCTCCACCACAGC-3′
R: 5′-GGCGGAAGCTTTTATGCATCAAAAAGCTCTCCAG-3′
751 Plasmid construction
F, forward primer; R, reverse primer. PCR conditions are described in Methods
Biochim Biophys Acta. Author manuscript; available in PMC 2018 February 01.
